Working Hard to Sell Ventilators Not Wanted by U.S.: Philips CEO

The transcript discusses Philips' 2021 growth guidance, highlighting the impact of COVID-19 on healthcare trends and the company's strategic positioning. It addresses the resurgence of COVID-19 in Europe and its effect on revenue, particularly in elective procedures. The cancellation of a large US ventilator order is examined, along with Philips' efforts to manage inventory and find new buyers. The discussion concludes with an assessment of global health preparedness for a second wave of COVID-19, emphasizing the importance of cloud technology and telehealth in future healthcare solutions.

What factors are influencing the guidance for low single-digit growth in 2021?

How is the demand for acute care equipment expected to change in the coming year?

What is the expected growth rate for Phillips from 2022 onwards?

What challenges are being faced in the diagnosis and treatment segment due to COVID-19?

What impact did the cancellation of ventilator orders have on the company?

How are governments better prepared for the second wave of COVID-19 compared to the first half of the year?

What strategies are being implemented to leverage cloud technology in healthcare?